BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23658295)

  • 1. Deja Vu: EGF receptors drive resistance to BRAF inhibitors.
    Girotti MR; Marais R
    Cancer Discov; 2013 May; 3(5):487-90. PubMed ID: 23658295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF as a therapeutic target: a patent review (2006 - 2012).
    Zambon A; Niculescu-Duvaz D; Niculescu-Duvaz I; Marais R; Springer CJ
    Expert Opin Ther Pat; 2013 Feb; 23(2):155-64. PubMed ID: 23294221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
    Montero-Conde C; Ruiz-Llorente S; Dominguez JM; Knauf JA; Viale A; Sherman EJ; Ryder M; Ghossein RA; Rosen N; Fagin JA
    Cancer Discov; 2013 May; 3(5):520-33. PubMed ID: 23365119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.
    Rebecca VW; Smalley KS
    Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427
    [No Abstract]   [Full Text] [Related]  

  • 9. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
    Cabanillas ME; Patel A; Danysh BP; Dadu R; Kopetz S; Falchook G
    Horm Cancer; 2015 Feb; 6(1):21-36. PubMed ID: 25467940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
    Zhang B; Chen Y; Dai P; Yu H; Ma J; Chen C; Zhang Y; Guan Y; Chen R; Liu T; Wang J; Yang L; Yi X; Xia X; Ma H
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1395. PubMed ID: 32757330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Curr Cancer Drug Targets; 2014; 14(2):128-43. PubMed ID: 24446739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking SOX10 to a slow-growth resistance phenotype.
    Zhang G; Herlyn M
    Cell Res; 2014 Aug; 24(8):906-7. PubMed ID: 24853952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in anti-BRAF therapies for lung cancer.
    Roviello G; D'Angelo A; Sirico M; Pittacolo M; Conter FU; Sobhani N
    Invest New Drugs; 2021 Jun; 39(3):879-890. PubMed ID: 33474634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.